EIF2AK2 and Alzheimer disease: All these findings argue for an early neuroinflammatory process in AD which could be secondarily driven by systemic inflammation and underline the fact that PKR could be a valid new therapeutic target to reduce neuroinflammation and AD brain lesions, to afford neuroprotection and improve memory in affected individuals33.